相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. G. Casali et al.
ANNALS OF ONCOLOGY (2022)
A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors
Arun S. Singh et al.
CLINICAL CANCER RESEARCH (2022)
Tyrosine Kinase Inhibition Alters Intratumoral CD8+ T-cell Subtype Composition and Activity
Andrew D. Tieniber et al.
CANCER IMMUNOLOGY RESEARCH (2022)
Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules
Christos Vallilas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Oncogenic KIT Modulates Type I IFN-Mediated Antitumor Immunity in GIST
Mengyuan Liu et al.
CANCER IMMUNOLOGY RESEARCH (2021)
An updated review of the treatment landscape for advanced gastrointestinal stromal tumors
Shreyaskumar R. Patel et al.
CANCER (2021)
Immunotherapy Strategies for Gastrointestinal Stromal Tumor
Junaid Arshad et al.
CANCERS (2021)
CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Valeria Leuci et al.
CLINICAL CANCER RESEARCH (2020)
Tumor genotype, location, and malignant potential shape the immunogenicity of primary untreated gastrointestinal stromal tumors
Daniela Gasparotto et al.
JCI INSIGHT (2020)
PD-1/PD-L1 blockade rescue exhausted CD8+T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway
Rui Zhao et al.
CELL PROLIFERATION (2019)
Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor
Gerardo A. Vitiello et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects
Alena Kalfusova et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era
W. T. A. van der Graaf et al.
BRITISH JOURNAL OF SURGERY (2018)
Defective HLA class I antigen processing machinery in cancer
Lei Cai et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.
Giulia Mesiano et al.
ONCOIMMUNOLOGY (2018)
Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis
J. Martin-Broto et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
Sandra P. D'Angelo et al.
CLINICAL CANCER RESEARCH (2017)
PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors
Adrian M. Seifert et al.
CLINICAL CANCER RESEARCH (2017)
Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events
Sebastian Huss et al.
HUMAN PATHOLOGY (2017)
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Matthew J. Reilley et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Current status of immunotherapy for gastrointestinal stromal tumor
Y. Tan et al.
CANCER GENE THERAPY (2017)
Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies
Kjetil Soreide et al.
CANCER EPIDEMIOLOGY (2016)
KIT, PDGFRA, and BRAF Mutational Spectrum Impacts on the Natural History of Imatinib-naive Localized GIST A Population-based Study
Sabrina Rossi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
PDL1 expression is an independent prognostic factor in localized GIST
Francois Bertucci et al.
ONCOIMMUNOLOGY (2015)
Cytokine-Induced Killer Cells Eradicate Bone and Soft-Tissue Sarcomas
Dario Sangiolo et al.
CANCER RESEARCH (2014)
Activity of cytokine-induced killer cells against bone and soft tissue sarcoma
Dario Sangiolo et al.
ONCOIMMUNOLOGY (2014)
Exploiting antitumor immunity to overcome relapse and improve remission duration
Lei L. Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
In vivo delivery of interferon-α gene enhances tumor immunity and suppresses immunotolerance in reconstituted lymphopenic hosts
K. Narumi et al.
GENE THERAPY (2012)
Combining targeted therapy with immunotherapy (interferon-α) Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies
Lei L. Chen et al.
ONCOIMMUNOLOGY (2012)
Histopathology of Gastrointestinal Stromal Tumor
Markku Miettinen et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
Gastrointestinal stromal tumours: origin and molecular oncology
Christopher L. Corless et al.
NATURE REVIEWS CANCER (2011)
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib
S Bauer et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on β2-microglobulin-associated and β2-microglobulin-free HLA class I heavy chains
SA Desai et al.
JOURNAL OF IMMUNOLOGY (2000)
Natural interferon α/β-producing cells link innate and adaptive immunity
N Kadowaki et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
